TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06150937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AEGIDA intervention arm
Description: The intervention arm has 4 sessions facilitated one-on-one by trained staff and lasting \~40 minutes. The first session focuses on establishing rapport, assessing HIV risk, and educating/training participants on HIV self-testing/PEP/PrEP. The second session on peer education/training, barriers to and facilitators of testing, and supporting peers in receiving reactive and/or indeterminate HIV test results, as well as self-care. The third session on stigma and discrimination and techniques to cope with and resist stigma. The final session is a culminating one focused on reviewing key skills and health promotion planning conducted in first three sessions. The intervention arm applies anti-intersectional stigma, empowerment, and harm reduction approaches. All participants will receive/have access to HIV self-test kits every three months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AEGIDA control arm
Description: The control arm has 4 sessions via one-on-one facilitation by a trained facilitator and lasting \~40 minutes. It includes basic information on self-screening for common adverse health conditions among women in Kazakhstan, including STIs and HIV, as well as information on testing and risk reduction. All participants will receive/have access to HIV self-test kits every three months.
Study: NCT04695834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maximal physiotherapy
Description: Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule
Study: NCT05364047

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0.5ml/person

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0.5ml/person
Study: NCT04661566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Education (Education)
Description: All participants will receive the basic educational component in the Mission Wellness app. This component will contain text and media (e.g., images, videos) to teach basic SRH topics. The exact information in this component will be determined by an assessment of baseline SRH knowledge at the start of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Education (Education)
Description: All participants will receive the basic educational component in the Mission Wellness app. This component will contain text and media (e.g., images, videos) to teach basic SRH topics. The exact information in this component will be determined by an assessment of baseline SRH knowledge at the start of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Education (Education)
Description: All participants will receive the basic educational component in the Mission Wellness app. This component will contain text and media (e.g., images, videos) to teach basic SRH topics. The exact information in this component will be determined by an assessment of baseline SRH knowledge at the start of the intervention.
Study: NCT05389137

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inavtivated Quadrivalent Influenza Virus Split Vaccine
Description: Prevent influenza caused by H1N1, H3N2, B (V), B (Y) strain virus infection.
Study: NCT05364047

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0.5ml/person

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0.5ml/person

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0.5ml/person
Study: NCT04744480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The combined topical anesthesia induction group
Description: The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
Study: NCT00006154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indinavir sulfate
Description: 400 mg tablets equaling 1600 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg liquid capsules equaling 400 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir sulfate
Description: 300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir sulfate
Description: 300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 200 mg capsules equaling 600 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 30-40 mg capsules equaling 60 or 80 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine
Description: 250-400 mg E.coated tablets equaling 250 or 400 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Didanosine
Description: 250-400 mg E.coated tablets equaling 250 or 400 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldesleukin
Description: Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
Study: NCT06534346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg DA-302168S tablet
Description: Qualified subjects will be randomly assigned to one of two dosing sequences in a 1:1 ratio. Either DA-302168S tablet with food on Day 1 and DA-302168S tablet without food on Day 6 (treatment sequence fed/fasted), or DA-302168S tablet without food on Day 1 and DA-302168S tablet with food on Day 6 (treatment sequence fasted/fed).~Each administration sequence consists of two cycles, with one administration per cycle and a 5-day washout period between each administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg DA-302168S tablet
Description: Qualified subjects will be randomly assigned to one of two dosing sequences in a 1:1 ratio. Either DA-302168S tablet with food on Day 1 and DA-302168S tablet without food on Day 6 (treatment sequence fed/fasted), or DA-302168S tablet without food on Day 1 and DA-302168S tablet with food on Day 6 (treatment sequence fasted/fed).~Each administration sequence consists of two cycles, with one administration per cycle and a 5-day washout period between each administration.
Study: NCT05650580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR115
Description: TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
Study: NCT04661566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Life Planning Tool (Future)
Description: The future life planning tool is a motivation-based component contains a series of questions to help users plan future goals to put current decision making related to SRH into perspective and provide suggestions on how to stay healthy now to be able to achieve those goals later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Life Planning Tool (Future)
Description: The future life planning tool is a motivation-based component contains a series of questions to help users plan future goals to put current decision making related to SRH into perspective and provide suggestions on how to stay healthy now to be able to achieve those goals later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Life Planning Tool (Future)
Description: The future life planning tool is a motivation-based component contains a series of questions to help users plan future goals to put current decision making related to SRH into perspective and provide suggestions on how to stay healthy now to be able to achieve those goals later.
Study: NCT05389137

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inavtivated Quadrivalent Influenza Virus Split Vaccine
Description: Prevent influenza caused by H1N1, H3N2, B (V), B (Y) strain virus infection.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inavtivated Quadrivalent Influenza Virus Split Vaccine
Description: Prevent influenza caused by H1N1, H3N2, B (V), B (Y) strain virus infection.
Study: NCT04433845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Open-label
Study: NCT06030297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser fiber type Selective Stimulator
Description: -Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fib
Study: NCT05480566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional strength training
Description: Functional strength training will include lower limb (e.g. rising from chair, heel rises) and upper limb (e.g. push-ups from the chair and against the wall) exercises for 15 min/day. Target levels of dyspnoea and/or perceived exertion will be 4 to 6 in the modified Borg scale.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: For neuromuscular electrical stimulation, electrodes will be placed longitudinally on the vastus intermedius and vastus medialis and a symmetric biphasic pulse waveform, with a pulse duration of 400ms, a frequency of 50Hz, in cycles of 8s of contraction and 20s of rest, will be used for 30min/day. The highest intensity tolerated by the patient will be used and intensity will be increased every time the patient feels comfortable with increasing the intensity. The device Compex Pro Rehab (CE-0473) will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine)
Description: Patients will be treated with daily medication prescribed by the physician, which can include oxygen, medrol, duovent, azitromycine or other medications that physicians consider that are needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine)
Description: Patients will be treated with daily medication prescribed by the physician, which can include oxygen, medrol, duovent, azitromycine or other medications that physicians consider that are needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physiotherapy
Description: Daily sessions of approximately 15 minutes consisting of airway clearance techniques and breathing exercises upon indication, mobilization, and low-intensity daily walking/cycling exercise (5 to 10 minutes) according to patients' tolerance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy
Description: Daily sessions of approximately 15 minutes consisting of airway clearance techniques and breathing exercises upon indication, mobilization, and low-intensity daily walking/cycling exercise (5 to 10 minutes) according to patients' tolerance.
Study: NCT05911854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-waved Locked System Laser
Description: The M6 therapy laser is a robotized multi-target device designed to treat patients suffering pathologies affecting a wide area, and to perform automatic applications.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Compression therapy
Description: The BioCryo Cold Compression System is a cold therapy pneumatic compression device that safely administers sequential, gradient pneumatic compression and CryoTherapy combined.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complete decongestive therapy
Description: Complete decongestive therapy consists of:~* Meticulous skin care with the use of emollients~* Using short stretch bandages or continuous wearing of a pressure garment~* Manual lymphatic drainage therapy~* Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complete decongestive therapy
Description: Complete decongestive therapy consists of:~* Meticulous skin care with the use of emollients~* Using short stretch bandages or continuous wearing of a pressure garment~* Manual lymphatic drainage therapy~* Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complete decongestive therapy
Description: Complete decongestive therapy consists of:~* Meticulous skin care with the use of emollients~* Using short stretch bandages or continuous wearing of a pressure garment~* Manual lymphatic drainage therapy~* Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)
Study: NCT06615531

Intervention type: BEHAVIORAL
Intervention: Advanced multi-component meditation practice
Description: The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
Study: NCT05850689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally, once daily
Study: NCT05462366

Intervention type: OTHER
Intervention: Sample collection
Description: Collect breast-milk and feces from mother-infant-pairs.

Intervention type: OTHER
Intervention: Sample collection
Description: Collect breast-milk and feces from mother-infant-pairs.
Study: NCT05577429

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-moderate intensity exercise under normoxia
Description: The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 20.9%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-moderate intensity exercise under moderate hypoxia
Description: The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 16.5%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-moderate intensity exercise under high hypoxia
Description: The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 14.8%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
Study: NCT06534515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomatis auditory stimulation
Description: Traditional Tomatis Method Protocol
Study: NCT04612179

Intervention type: DEVICE
Intervention: The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system
Description: Investigational device: SUPRAFLEX CRUZ™ Sirolimus eluting Coronary Stent System The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system consists of a balloon ex-pandable Sirolimus eluting stent, premounted on a stent delivery system. The active pharmaceutical ingredient in the SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent is Sirolimus (also known as Rapamycin).~The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system is indicated for improving coronary luminal diameter in patients with symptomatic Ischemic heart disease due to discrete de-novo stenotic lesions and in-stent restenotic lesions in native coronary arter-ies with a reference vessel diameter of 2.00 mm to 4.50 mm.
Study: NCT04391231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline Oral Product
Description: Blinded Pentoxifylline (in suspension with SyrSpend SF)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (SyrSpend SF only)
Study: NCT05403489

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.

Intervention type: PROCEDURE
Intervention: endotracheal aspirate culture
Description: In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
Study: NCT04781153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: Periodontal treatment (scaling and rootplaning) with adjunctive chlorhexidine use

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: Periodontal treatment (scaling and rootplaning) with adjunctive chlorhexidine use
Study: NCT05014165

Intervention type: OTHER
Intervention: Cord blood Sample Collection
Description: Obtain banked cord blood samples from consecutive childhood leukemia patients

Intervention type: OTHER
Intervention: Case identification and recruitment
Description: Cases meeting eligibility and who have given consent through APEC14B1 for future contact for non-therapeutic studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: The family will be given an option to complete questionnaire on paper, online, or over the telephone.
Study: NCT06068686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG
Description: vildagliptin plus their metformin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 3 Mg Oral Tablet
Description: glimepiride plus their metformin
Study: NCT05057234

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FoundationOne liquid CDx
Description: FoundationOne liquid CDx testing

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FoundationOne liquid CDx
Description: FoundationOne liquid CDx testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Description: Quality of life questionnaire - EQ5D

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Description: Quality of life questionnaire - EQ5D

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Description: Quality of life questionnaire - EQ5D
Study: NCT06381596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OcuMet Beacon
Description: OcuMet Beacon is a novel fundus camera the can detect, capture, and assess FPF.
Study: NCT05363852

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard set of visual word and picture stimuli
Description: Set ot 145 stimuli: 115 words (three sets of 35 words with positive, neutral, and negative content) and 30 pictures (two sets of 15 photos with positive and negative content).
Study: NCT05403723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 50 MG/1 ML Intravenous Solution
Description: Durvalumab (1500 mg durvalumab via IV infusion) in combination with platinum doublet chemotherapy will be administered to patients once every 3 weeks for up to 4 cycles plus SBRT (platinum resistant group) or without SBRT (platinum sensitive group). Each 3-week of chemoimmunotherapy interval is considered a cycle. Patients with platinum sensitive disease will receive the combination of durvalumab and chemotherapy (total of four cycles) while those with platinum resistant SCLC will receive SBRT and continue to receive up to two additional cycles of treatment with durvalumab along with platinum/etoposide (not to exceed a total of four6 cycles of chemoimmunotherapy including 2 cycles obtained prior to SBRT). Following completion of 4-6 cycles of combination therapy, patients in both groups will continue with maintenance durvalumab (1500 mg) in q4w cycles until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Injection
Description: A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Patients will receive palliative radiation to the primary tumor site up to 30 Gy for 1 week given as 5 daily fractions of 6 Gy each or 27 Gy as 3 fractions of 9 Gy administered every other day.
Study: NCT04596930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser ablation thermal therapy
Description: The Visualase Thermal Therapy System is used to necrotize or coagulate soft tissue through interstitial irradiation under MRI guidance